The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-CD47 Antibody Market Research Report 2025

Global Anti-CD47 Antibody Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1897614

No of Pages : 100

Ask Your Query
Synopsis
An Anti-CD47 Antibody is a type of antibody that targets the CD47 protein, which is overexpressed in various types of cancer cells. CD47 acts as a "don't eat me" signal, preventing the immune system's macrophages from engulfing and destroying cancer cells. The Anti-CD47 Antibody works by blocking the CD47 protein, thereby allowing the immune system to recognize and eliminate cancer cells effectively. This antibody has shown promise as a potential therapeutic agent in cancer immunotherapy, as it enhances the body's natural immune response against cancer while minimizing toxic side effects.
The global Anti-CD47 Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The industry trend of Anti-CD47 Antibody is highly promising and gaining significant attention in the field of cancer research and drug development. Several pharmaceutical companies and research institutions are actively pursuing the development of Anti-CD47 Antibody-based therapies. There is a growing interest in combining this antibody with other immuno-oncology agents, such as checkpoint inhibitors, to enhance its therapeutic efficacy. Clinical trials evaluating the safety and efficacy of Anti-CD47 Antibody treatments in various cancer types are ongoing and showing encouraging results. The advancement of precision medicine and personalized cancer therapies further supports the potential of Anti-CD47 Antibody as a valuable addition to the oncology treatment armamentarium.
This report aims to provide a comprehensive presentation of the global market for Anti-CD47 Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-CD47 Antibody.
Report Scope
The Anti-CD47 Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-CD47 Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-CD47 Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BosterBio
Leinco Technologies
Bioss
Novus Biologicals
Thermo Fisher Scientific
Biorbyt
Abbexa
Bio X Cell
GeneTex
R&D Systems
LSBio
MyBioSource
ProSci
antibodies-online
ABclonal Technology
Abnova Corporation
G Biosciences
BioLegend
Bio-Rad
Huabio
BPS Bioscience
OriGene Technologies
St John's Laboratory
Absolute Antibody
NSJ Bioreagents
Cell Signaling Technology
RayBiotech
Beijing Solarbio Science & Technology
Bethyl Laboratories
Abeomics
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-CD47 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-CD47 Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Anti-CD47 Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-CD47 Antibody Market Perspective (2019-2030)
2.2 Anti-CD47 Antibody Growth Trends by Region
2.2.1 Global Anti-CD47 Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-CD47 Antibody Historic Market Size by Region (2019-2024)
2.2.3 Anti-CD47 Antibody Forecasted Market Size by Region (2025-2030)
2.3 Anti-CD47 Antibody Market Dynamics
2.3.1 Anti-CD47 Antibody Industry Trends
2.3.2 Anti-CD47 Antibody Market Drivers
2.3.3 Anti-CD47 Antibody Market Challenges
2.3.4 Anti-CD47 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-CD47 Antibody Players by Revenue
3.1.1 Global Top Anti-CD47 Antibody Players by Revenue (2019-2024)
3.1.2 Global Anti-CD47 Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Anti-CD47 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-CD47 Antibody Revenue
3.4 Global Anti-CD47 Antibody Market Concentration Ratio
3.4.1 Global Anti-CD47 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-CD47 Antibody Revenue in 2023
3.5 Anti-CD47 Antibody Key Players Head office and Area Served
3.6 Key Players Anti-CD47 Antibody Product Solution and Service
3.7 Date of Enter into Anti-CD47 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-CD47 Antibody Breakdown Data by Type
4.1 Global Anti-CD47 Antibody Historic Market Size by Type (2019-2024)
4.2 Global Anti-CD47 Antibody Forecasted Market Size by Type (2025-2030)
5 Anti-CD47 Antibody Breakdown Data by Application
5.1 Global Anti-CD47 Antibody Historic Market Size by Application (2019-2024)
5.2 Global Anti-CD47 Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-CD47 Antibody Market Size (2019-2030)
6.2 North America Anti-CD47 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-CD47 Antibody Market Size by Country (2019-2024)
6.4 North America Anti-CD47 Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-CD47 Antibody Market Size (2019-2030)
7.2 Europe Anti-CD47 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-CD47 Antibody Market Size by Country (2019-2024)
7.4 Europe Anti-CD47 Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-CD47 Antibody Market Size (2019-2030)
8.2 Asia-Pacific Anti-CD47 Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-CD47 Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-CD47 Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-CD47 Antibody Market Size (2019-2030)
9.2 Latin America Anti-CD47 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-CD47 Antibody Market Size by Country (2019-2024)
9.4 Latin America Anti-CD47 Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-CD47 Antibody Market Size (2019-2030)
10.2 Middle East & Africa Anti-CD47 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-CD47 Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-CD47 Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BosterBio
11.1.1 BosterBio Company Detail
11.1.2 BosterBio Business Overview
11.1.3 BosterBio Anti-CD47 Antibody Introduction
11.1.4 BosterBio Revenue in Anti-CD47 Antibody Business (2019-2024)
11.1.5 BosterBio Recent Development
11.2 Leinco Technologies
11.2.1 Leinco Technologies Company Detail
11.2.2 Leinco Technologies Business Overview
11.2.3 Leinco Technologies Anti-CD47 Antibody Introduction
11.2.4 Leinco Technologies Revenue in Anti-CD47 Antibody Business (2019-2024)
11.2.5 Leinco Technologies Recent Development
11.3 Bioss
11.3.1 Bioss Company Detail
11.3.2 Bioss Business Overview
11.3.3 Bioss Anti-CD47 Antibody Introduction
11.3.4 Bioss Revenue in Anti-CD47 Antibody Business (2019-2024)
11.3.5 Bioss Recent Development
11.4 Novus Biologicals
11.4.1 Novus Biologicals Company Detail
11.4.2 Novus Biologicals Business Overview
11.4.3 Novus Biologicals Anti-CD47 Antibody Introduction
11.4.4 Novus Biologicals Revenue in Anti-CD47 Antibody Business (2019-2024)
11.4.5 Novus Biologicals Recent Development
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Company Detail
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Anti-CD47 Antibody Introduction
11.5.4 Thermo Fisher Scientific Revenue in Anti-CD47 Antibody Business (2019-2024)
11.5.5 Thermo Fisher Scientific Recent Development
11.6 Biorbyt
11.6.1 Biorbyt Company Detail
11.6.2 Biorbyt Business Overview
11.6.3 Biorbyt Anti-CD47 Antibody Introduction
11.6.4 Biorbyt Revenue in Anti-CD47 Antibody Business (2019-2024)
11.6.5 Biorbyt Recent Development
11.7 Abbexa
11.7.1 Abbexa Company Detail
11.7.2 Abbexa Business Overview
11.7.3 Abbexa Anti-CD47 Antibody Introduction
11.7.4 Abbexa Revenue in Anti-CD47 Antibody Business (2019-2024)
11.7.5 Abbexa Recent Development
11.8 Bio X Cell
11.8.1 Bio X Cell Company Detail
11.8.2 Bio X Cell Business Overview
11.8.3 Bio X Cell Anti-CD47 Antibody Introduction
11.8.4 Bio X Cell Revenue in Anti-CD47 Antibody Business (2019-2024)
11.8.5 Bio X Cell Recent Development
11.9 GeneTex
11.9.1 GeneTex Company Detail
11.9.2 GeneTex Business Overview
11.9.3 GeneTex Anti-CD47 Antibody Introduction
11.9.4 GeneTex Revenue in Anti-CD47 Antibody Business (2019-2024)
11.9.5 GeneTex Recent Development
11.10 R&D Systems
11.10.1 R&D Systems Company Detail
11.10.2 R&D Systems Business Overview
11.10.3 R&D Systems Anti-CD47 Antibody Introduction
11.10.4 R&D Systems Revenue in Anti-CD47 Antibody Business (2019-2024)
11.10.5 R&D Systems Recent Development
11.11 LSBio
11.11.1 LSBio Company Detail
11.11.2 LSBio Business Overview
11.11.3 LSBio Anti-CD47 Antibody Introduction
11.11.4 LSBio Revenue in Anti-CD47 Antibody Business (2019-2024)
11.11.5 LSBio Recent Development
11.12 MyBioSource
11.12.1 MyBioSource Company Detail
11.12.2 MyBioSource Business Overview
11.12.3 MyBioSource Anti-CD47 Antibody Introduction
11.12.4 MyBioSource Revenue in Anti-CD47 Antibody Business (2019-2024)
11.12.5 MyBioSource Recent Development
11.13 ProSci
11.13.1 ProSci Company Detail
11.13.2 ProSci Business Overview
11.13.3 ProSci Anti-CD47 Antibody Introduction
11.13.4 ProSci Revenue in Anti-CD47 Antibody Business (2019-2024)
11.13.5 ProSci Recent Development
11.14 antibodies-online
11.14.1 antibodies-online Company Detail
11.14.2 antibodies-online Business Overview
11.14.3 antibodies-online Anti-CD47 Antibody Introduction
11.14.4 antibodies-online Revenue in Anti-CD47 Antibody Business (2019-2024)
11.14.5 antibodies-online Recent Development
11.15 ABclonal Technology
11.15.1 ABclonal Technology Company Detail
11.15.2 ABclonal Technology Business Overview
11.15.3 ABclonal Technology Anti-CD47 Antibody Introduction
11.15.4 ABclonal Technology Revenue in Anti-CD47 Antibody Business (2019-2024)
11.15.5 ABclonal Technology Recent Development
11.16 Abnova Corporation
11.16.1 Abnova Corporation Company Detail
11.16.2 Abnova Corporation Business Overview
11.16.3 Abnova Corporation Anti-CD47 Antibody Introduction
11.16.4 Abnova Corporation Revenue in Anti-CD47 Antibody Business (2019-2024)
11.16.5 Abnova Corporation Recent Development
11.17 G Biosciences
11.17.1 G Biosciences Company Detail
11.17.2 G Biosciences Business Overview
11.17.3 G Biosciences Anti-CD47 Antibody Introduction
11.17.4 G Biosciences Revenue in Anti-CD47 Antibody Business (2019-2024)
11.17.5 G Biosciences Recent Development
11.18 BioLegend
11.18.1 BioLegend Company Detail
11.18.2 BioLegend Business Overview
11.18.3 BioLegend Anti-CD47 Antibody Introduction
11.18.4 BioLegend Revenue in Anti-CD47 Antibody Business (2019-2024)
11.18.5 BioLegend Recent Development
11.19 Bio-Rad
11.19.1 Bio-Rad Company Detail
11.19.2 Bio-Rad Business Overview
11.19.3 Bio-Rad Anti-CD47 Antibody Introduction
11.19.4 Bio-Rad Revenue in Anti-CD47 Antibody Business (2019-2024)
11.19.5 Bio-Rad Recent Development
11.20 Huabio
11.20.1 Huabio Company Detail
11.20.2 Huabio Business Overview
11.20.3 Huabio Anti-CD47 Antibody Introduction
11.20.4 Huabio Revenue in Anti-CD47 Antibody Business (2019-2024)
11.20.5 Huabio Recent Development
11.21 BPS Bioscience
11.21.1 BPS Bioscience Company Detail
11.21.2 BPS Bioscience Business Overview
11.21.3 BPS Bioscience Anti-CD47 Antibody Introduction
11.21.4 BPS Bioscience Revenue in Anti-CD47 Antibody Business (2019-2024)
11.21.5 BPS Bioscience Recent Development
11.22 OriGene Technologies
11.22.1 OriGene Technologies Company Detail
11.22.2 OriGene Technologies Business Overview
11.22.3 OriGene Technologies Anti-CD47 Antibody Introduction
11.22.4 OriGene Technologies Revenue in Anti-CD47 Antibody Business (2019-2024)
11.22.5 OriGene Technologies Recent Development
11.23 St John's Laboratory
11.23.1 St John's Laboratory Company Detail
11.23.2 St John's Laboratory Business Overview
11.23.3 St John's Laboratory Anti-CD47 Antibody Introduction
11.23.4 St John's Laboratory Revenue in Anti-CD47 Antibody Business (2019-2024)
11.23.5 St John's Laboratory Recent Development
11.24 Absolute Antibody
11.24.1 Absolute Antibody Company Detail
11.24.2 Absolute Antibody Business Overview
11.24.3 Absolute Antibody Anti-CD47 Antibody Introduction
11.24.4 Absolute Antibody Revenue in Anti-CD47 Antibody Business (2019-2024)
11.24.5 Absolute Antibody Recent Development
11.25 NSJ Bioreagents
11.25.1 NSJ Bioreagents Company Detail
11.25.2 NSJ Bioreagents Business Overview
11.25.3 NSJ Bioreagents Anti-CD47 Antibody Introduction
11.25.4 NSJ Bioreagents Revenue in Anti-CD47 Antibody Business (2019-2024)
11.25.5 NSJ Bioreagents Recent Development
11.26 Cell Signaling Technology
11.26.1 Cell Signaling Technology Company Detail
11.26.2 Cell Signaling Technology Business Overview
11.26.3 Cell Signaling Technology Anti-CD47 Antibody Introduction
11.26.4 Cell Signaling Technology Revenue in Anti-CD47 Antibody Business (2019-2024)
11.26.5 Cell Signaling Technology Recent Development
11.27 RayBiotech
11.27.1 RayBiotech Company Detail
11.27.2 RayBiotech Business Overview
11.27.3 RayBiotech Anti-CD47 Antibody Introduction
11.27.4 RayBiotech Revenue in Anti-CD47 Antibody Business (2019-2024)
11.27.5 RayBiotech Recent Development
11.28 Beijing Solarbio Science & Technology
11.28.1 Beijing Solarbio Science & Technology Company Detail
11.28.2 Beijing Solarbio Science & Technology Business Overview
11.28.3 Beijing Solarbio Science & Technology Anti-CD47 Antibody Introduction
11.28.4 Beijing Solarbio Science & Technology Revenue in Anti-CD47 Antibody Business (2019-2024)
11.28.5 Beijing Solarbio Science & Technology Recent Development
11.29 Bethyl Laboratories
11.29.1 Bethyl Laboratories Company Detail
11.29.2 Bethyl Laboratories Business Overview
11.29.3 Bethyl Laboratories Anti-CD47 Antibody Introduction
11.29.4 Bethyl Laboratories Revenue in Anti-CD47 Antibody Business (2019-2024)
11.29.5 Bethyl Laboratories Recent Development
11.30 Abeomics
11.30.1 Abeomics Company Detail
11.30.2 Abeomics Business Overview
11.30.3 Abeomics Anti-CD47 Antibody Introduction
11.30.4 Abeomics Revenue in Anti-CD47 Antibody Business (2019-2024)
11.30.5 Abeomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock